WuXi Biologics Receives UK MHRA GMP Certification, Accelerating Commercial Production of Innovative Ophthalmic Biologics
January 14, 2026
Source: drugdu
34
WuXi Biologics recently announced that its two manufacturing plants in Wuxi—Plant 5 (DP5) and the Formulation Packaging Centre (DPPC)—have received GMP certification from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to provide commercial manufacturing services for an innovative ophthalmic biologic. WuXi Biologics will provide end -to-end manufacturing services for this ophthalmic biologic, covering both the drug substance and the formulation.
https://finance.eastmoney.com/a/202601133616465680.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- 1.2 Billion Yuan! Sino Biopharm Acquires Another Pharmaceutical Company January 15, 2026
- Breakthrough! Changshan Pharmaceutical’s enoxaparin sodium injection receives FDA approval in the United States, marking a new chapter in its overseas market journey! January 15, 2026
- Kelun and Grand Pharmaceuticals compete for the first generic version of a blockbuster heart failure drug! January 15, 2026
- Xuesaitong soft capsules are the company’s exclusive core dosage form January 15, 2026
- Hualan Biological’s investee company’s application for marketing authorization of adalimumab injection has been accepted January 15, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
